Cellectar Biosciences Inc
NASDAQ:CLRB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CLRB's latest stock split occurred on Jun 24, 2025
The company executed a 1-for-30 stock split, meaning that for every 30 shares held, investors received 1 new share.
Before the split, CLRB traded at 0.2978 per share. Afterward, the share price was about 9.7.
The adjusted shares began trading on Jun 24, 2025. This was CLRB's 7th stock split, following the previous one in Jul 22, 2022.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 22, 2026
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
1-for-100
/100
|
0.002 0.2 AUD | 0.17 0.17 AUD |
|
Apr 22, 2026
|
|
Architects Studio Japan Inc
TSE:6085
|
10-for-1
x10
|
3800 380 JPY | 430 430 JPY |
|
Apr 22, 2026
|
|
Freewon China Co Ltd
SSE:688678
|
1-for-1
x1
|
30.5 21.6857 CNY | 23.64 23.64 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
|
Apr 21, 2026
|
|
Canon Electronics Inc
OTC:CAOEF
|
1-for-6235122
/6235122
|
16.96 16.96 USD | N/A |
CHM
6085
688678
CAOEF
Cellectar Biosciences Inc
Glance View
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through Phospholipid Drug Conjugate (PDC) platform, is focused on to develop PDCs that are designed to target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The Company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The firm is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase II CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase II CLOVER-2 study.
